172 related articles for article (PubMed ID: 33466719)
1. Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC).
Economopoulou P; Anastasiou M; Papaxoinis G; Spathas N; Spathis A; Oikonomopoulos N; Kotsantis I; Tsavaris O; Gkotzamanidou M; Gavrielatou N; Vagia E; Kyrodimos E; Gagari E; Giotakis E; Delides A; Psyrri A
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33466719
[No Abstract] [Full Text] [Related]
2. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
Park JH; Chun SH; Lee YG; Chang H; Lee KW; Kim HR; Shin SH; An HJ; Lee KE; Hwang IG; Ahn MJ; Kim SB; Keam B
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3359-3369. PubMed ID: 32671504
[TBL] [Abstract][Full Text] [Related]
3. Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma.
Karabajakian A; Garrivier T; Crozes C; Gadot N; Blay JY; Bérard F; Céruse P; Zrounba P; Saintigny P; Mastier C; Fayette J
Oncotarget; 2020 May; 11(18):1618-1628. PubMed ID: 32405337
[No Abstract] [Full Text] [Related]
4. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Saâda-Bouzid E; Defaucheux C; Karabajakian A; Coloma VP; Servois V; Paoletti X; Even C; Fayette J; Guigay J; Loirat D; Peyrade F; Alt M; Gal J; Le Tourneau C
Ann Oncol; 2017 Jul; 28(7):1605-1611. PubMed ID: 28419181
[TBL] [Abstract][Full Text] [Related]
5. Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy.
Wang M; Huang H; Xu Z; Li Z; Shen L; Yu Y; Lu S
Lung Cancer; 2022 Nov; 173():28-34. PubMed ID: 36116167
[TBL] [Abstract][Full Text] [Related]
6. The genomic characteristics of different progression patterns in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Li J; Xiang C; Wang Y; Zhou Y; Cao S; Ling X; Ye J; Zheng J; Shao L; Zhong H; Han Y
Ann Transl Med; 2021 May; 9(9):779. PubMed ID: 34268392
[TBL] [Abstract][Full Text] [Related]
7. Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer.
Wang Z; Liu C; Bai Y; Zhao X; Cui L; Peng Z; Zhang X; Wang X; Zhao Z; Li J; Shen L
Front Oncol; 2021; 11():761110. PubMed ID: 34858840
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
Arribas L; Plana M; Taberna M; Sospedra M; Vilariño N; Oliva M; Pallarés N; González Tampán AR; Del Rio LM; Mesia R; Baracos V
Front Oncol; 2021; 11():699668. PubMed ID: 34249760
[TBL] [Abstract][Full Text] [Related]
9. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
10. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
11. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
[TBL] [Abstract][Full Text] [Related]
12. Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.
Maesaka K; Sakamori R; Yamada R; Tahata Y; Imai Y; Ohkawa K; Miyazaki M; Mita E; Ito T; Hagiwara H; Yakushijin T; Kodama T; Hikita H; Tatsumi T; Takehara T
Hepatol Res; 2022 Mar; 52(3):298-307. PubMed ID: 34918428
[TBL] [Abstract][Full Text] [Related]
13. Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa.
Yang CC; Lien CF; Hwang TZ; Wang CC; Wang CC; Shih YC; Yeh SA; Hsieh MC
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625956
[TBL] [Abstract][Full Text] [Related]
14. Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics.
Singla R; Gupta A; Batra U; Chaturvedi A; Rao A; Jajodia A
Indian J Radiol Imaging; 2021 Apr; 31(2):345-349. PubMed ID: 34556917
[No Abstract] [Full Text] [Related]
15. Is there an association between lymph node size and hyperprogression in immunotherapy-treated patients?
Alkader MS; Altaha RZ; Jabali EH; Attieh OA; Matalqa AW
Rom J Intern Med; 2024 Mar; 62(1):33-43. PubMed ID: 37882575
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC.
Rocha P; Ramal D; Ripoll E; Moliner L; Corbera A; Hardy-Werbin M; Orrillo M; Taus Á; Zuccarino F; Gibert J; Perera-Bel J; Casadevall D; Arriola E
JTO Clin Res Rep; 2021 Jan; 2(1):100115. PubMed ID: 34589976
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor.
Kim Y; Kim CH; Lee HY; Lee SH; Kim HS; Lee S; Cha H; Hong S; Kim K; Seo SW; Sun JM; Ahn MJ; Ahn JS; Park K
J Thorac Oncol; 2019 Sep; 14(9):1608-1618. PubMed ID: 31195179
[TBL] [Abstract][Full Text] [Related]
18. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
19. Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study.
Long Y; Yang W; Bai Y; Tao H; Zhang F; Wang L; Yang B; Huang D; Han X; Hu Y
Cancer Cell Int; 2023 Sep; 23(1):224. PubMed ID: 37777758
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease.
Kim SH; Choi CM; Lee DH; Kim SW; Yoon S; Kim WS; Ji W; Lee JC
J Cancer Res Clin Oncol; 2020 Nov; 146(11):3025-3036. PubMed ID: 32583235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
